Address
Email address
Phone number
https://icosagen.eeKoduleht - IcosagenMuudame ideed reaalsuseks Icosagen on pühendunud Eesti biotehnoloogiaettevõte, mis tegeleb terapeutiliste antikehade arendamise ja diagnostiliste rekombinantsete valkude tootmisega imetajate rakkudes nii teadusuuringute kui ka in vitro diagnostika tarbeks. Loe lisaks Meist Teenused Klientide tagasiside “Fast responses, great flexibility, transparency, collaborative spirit, high quality” Ridgeline Kliki siia”Fast reply, quality of reports, good product profile” Pharis Biofarmaceuticals […]
Name
Amplikon OÜ
Registry code
12860392
VAT number
EE102547775
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
03.06.2015 (9)
Financial year
01.01-31.12
Capital
3 000.00 €
Activity
69202 - Bookkeeping, tax consulting
-
-
-
-
-
-
-
No tax arrears
-
-
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Mart Ustav
| 100% - 3 000.00 EUR | Board member | - | Founder |
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| Icosagen AS 10565884 | 96% - 184 838.40 EUR | - | - | Shareholder |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q4 | - | - | - | - |
| 2024 Q3 | - | - | - | - |
| 2024 Q2 | - | - | - | - |
| 2024 Q1 | 18 989.29 € | 11 968.07 € | 8 923.59 € | - |
| 2023 Q4 | 15 044 € | 8 618.24 € | 6 119.04 € | 1 |
| 2023 Q3 | 19 231 € | 8 932.47 € | 5 859.95 € | 1 |
| 2023 Q2 | 19 685 € | 11 808.61 € | 8 695.99 € | 1 |
| 2023 Q1 | 19 392 € | 9 552.75 € | 6 461.13 € | 1 |
| 2022 Q4 | 13 585 € | 7 390.5 € | 5 189.33 € | 1 |
| 2022 Q3 | - | 5 130.76 € | 5 562.57 € | 1 |
| 2022 Q2 | - | 5 280.28 € | 5 724.68 € | 1 |
| 2022 Q1 | - | 2 520.71 € | 2 732.86 € | 1 |
| 2021 Q4 | - | - | - | 1 |
